A prospective study of serum folate levels in patients with solid tumors treated with olaparib
This trial demonstrated folate deficiency in nearly all patients starting olaparib within weeks but, deficiencies did not result in a clinically significant anemia. Folate levels normalized with supplementation and improved with olaparib discontinuation. This data warrant checking serum folate in patients receiving olaparib who develop anemia and replacing folate if deficiency is found.
Authors
- Sanjib Basu (ORCID: https://orcid.org/0000-0001-5607-4058)
- Summer Dewdney (ORCID: https://orcid.org/0000-0002-3576-4591)
- Jamile M. Shammo
- Laura Owczarzak (ORCID: https://orcid.org/0000-0003-2958-9245)
- Melody Cobleigh (ORCID: https://orcid.org/0000-0001-6385-4693)
- Ruta Rao (ORCID: https://orcid.org/0000-0003-3037-2318)
- Nicole K. Yun (ORCID: https://orcid.org/0000-0002-3668-9618)
- L. Winkelman
- Lydia Usha (ORCID: https://orcid.org/0000-0001-5968-5487)
- Amina Ahmed (ORCID: https://orcid.org/0000-0001-9494-742X)
Institutions
- Northwestern University (US)
- Rush University Medical Center (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-09-27
- DOI
- https://doi.org/10.1093/oncolo/oyaf321
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca